Progenics Pharma Balance Sheet - Quarterly (NASDAQ:PGNX)

Add to My Stocks
$6.57 $0.15 (2.34%) PGNX stock closing price Sep 20, 2018 (Closing)

A thorough fundamental analysis involves using data from Progenics Pharma balance sheet, apart from other financial statements, to value the business. All three financial statements should be used to measure the financial performance of the company, and should form a part of the Progenics Pharma stock analysis. Quarterly results are typically accompanied with the company releasing financial statements. Progenics Pharma had a long term debt of $42.88M at the end of 2018 Q2. To understand the debt servicing capacity of the company, one needs to look at Progenics Pharma operating cash flow and Progenics Pharma revenue also. Progenics Pharma debt to equity ratio is 0.76.

View and download Progenics Pharma quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Marketable Securities----------
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets2.18M2.45M2.25M1.66M3.26M3.67M4.32M3.77M5.33M5.12M
Total Current Assets
Property Plant & Equipment--5.83M---5.59M---
Accumulated Depreciation--1.71M-------
Net Property Plant & Equipment
Investment & Advances----------
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets1.53M1.52M1.52M2.47M2.47M2.47M2.47M2.71M1.69M1.69M
Total Assets
Notes Payable----------
Accounts Payable-1.59M3.35M1.11M1.13M--1.1M1.06M1.5M
Current Portion Long-Term Debt4.77M4.73M2.44M1.83M1.24M-----
Current Portion Capital Leases----------
Accrued Expenses9.44M7.92M9.55M10.1M14.1M12.7M15.76M12.69M12.05M9.74M
Income Taxes Payable----------
Other Current Liabilities----------
Total Current Liabilities
Deferred Taxes/Income1.48M1.57M1.57M13.01M13.01M13.01M13.01M11.19M11.19M-
Convertible Debt----------
Long-Term Debt42.88M45.01M47.24M47.78M48.32M48.85M49.45M---
Non-Current Capital Leases----------
Other Long-Term Liabilities20.57M19.2M18.32M18.94M18.16M17.38M15.4M20.88M19.73M31.17M
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus635.71M619.04M609.82M601.68M600.82M598.9M598.06M596.97M596.05M595.08M
Retained Earnings-570.15M-554.97M-541.58M-538.92M-523.56M-506.93M-490.57M-483.36M-519.67M-514.03M
Treasury Stock2.74M2.74M2.74M2.74M2.74M2.74M2.74M2.74M2.74M2.74M
Other Liabilities-0.09M-0.8M-2.14M-0.03M-0.05M-0.06M-0.08M---
Shareholders Equity62.83M60.61M63.45M60.08M74.55M89.25M104.76M111.03M73.83M78.49M
Total Liabilities & Shareholders Equity142.51M140.66M145.95M152.88M170.52M182.85M198.98M156.93M118.2M121.03M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Most investors just check the Progenics Pharma stock price, and Progenics Pharma historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Progenics Pharma PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: An asset is a resource that a corporation like Progenics Pharma owns and has monetary significance. PGNX assets grew from $140.66M in 2018 Q1 to $142.51M in 2018 Q2. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities include short term loans and long term loans availed by the company to fund its business operations. PGNX stock had total liabilities of $79.68M for the quarter 2018 Q2.

Progenics Pharma Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio